Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSCAR: Oritavancin for Gram-positive Cardiac Infections
NCT07550595Phase 2Not yet recruiting
- Sponsor
- The Kirby Institute
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oritavancin in infective endocarditis (IE), cardiovascular implantable electronic device infection (CIED-I), sponsored by The Kirby Institute. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
oritavancin
03
Conditions
infective endocarditis (IE)cardiovascular implantable electronic device infection (CIED-I)
Beyond the preview
Go deeper on NCT07550595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550595.